Novartis to buy 25% of Alcon

Novartis is to purchase 25% of Alcon from majority stakeholder Nestlé, with an option to purchase Nestlé's remaining shares, which currently amount to approximately 52% of Alcon.

Related Content:

ArticlesCataract & Refractive

Removing opioid prescriptions from cataract surgery

iScan 80 OCT to launch in UK

Managing long COVID-19 symptoms that persist beyond infection